Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · February 19, 2024

Dose–Response Effects of Survodutide vs Semaglutide on HbA1c Level and Bodyweight Reductions in People With Type 2 Diabetes



Additional Info

Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
Diabetologia 2024 Mar 01;67(3)470-482, M Blüher, J Rosenstock, J Hoefler, R Manuel, AM Hennige

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading